title: [The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation].
abstract: METHODS
  Three years ago, a now 26-year-old woman with secondary amenorrhoea was found to have a prolactinoma which was treated with bromocriptine. However, because of side effects and psychosocial problems she took the drug only irregularly. There were no neurological symptoms and the visual fields were normal. Her weight was 97 kg and her height 168 cm.
  
  
  METHODS
  Without treatment the serum prolactin concentration was 6978 microU/ml, while other endocrine parameters were unremarkable. Cranial computed tomography showed a suprasellar adenoma (craniocaudal diameter 1.0 cm).
  
  
  METHODS
  Renewed treatment with bromocriptine (5 mg three times daily) brought prolactin concentration to within normal limits, but then rose again to at least 52,600 microU/ml when the patient took the drug irregularly, and the tumour grew to 2.8 cm. As the obesity (her weight now 120 kg) made neurosurgical intervention very risky a treatment trial with long-acting bromocriptine preparation (50 mg bromocriptine every 28 days intramuscularly), was undertaken. Serum prolactin concentration, measured at the end of the 28-day period, rapidly fell (6470 microU/ml after 3 months). Radiological examination indicated significant tumour shrinkage ( < 1.0 cm after 2 years).
  
  
  CONCLUSIONS
  Repeated intramuscular administration of bromocriptine was an effective, well tolerated alternative (but not yet licensed in Germany) to oral dopamine agonists in the treatment of macroprolactinoma.
authors.affiliation: Klinik für Innere Medizin I, Medizinische Universität Lübeck.
authors.forename: B
authors.initials: B
authors.lastname: Kreft
authors.forename: A
authors.initials: A
authors.lastname: Peters
authors.forename: W
authors.initials: W
authors.lastname: Kerner
mesh_terms: D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D015175:Prolactinoma / Q000097:blood / Q000188:drug therapy*; D012074:Remission Induction; D013997:Time Factors
chemical_list: D003692:Delayed-Action Preparations; D018491:Dopamine Agonists; D001971:Bromocriptine; D011388:Prolactin
vernacular_title: Therapie eines Makroprolaktinoms durch intramuskuläre Applikation eines langwirksamen Bromocriptin-Präparates.